메뉴 건너뛰기




Volumn 29, Issue 9, 2014, Pages 1205-1211

Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis

Author keywords

Ankylosing; Arthritis; Rheumatoid; Spondylitis; Survival; TNF inhibitor

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

EID: 84929942531     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2014.29.9.1205     Document Type: Article
Times cited : (28)

References (34)
  • 2
    • 7044227565 scopus 로고    scopus 로고
    • Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues
    • Wolfe F, Michaud K, Dewitt EM. Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. Ann Rheum Dis 2004; 63 Suppl 2: ii13-7.
    • (2004) Ann Rheum Dis , vol.63 , pp. ii13-ii17
    • Wolfe, F.1    Michaud, K.2    Dewitt, E.M.3
  • 3
    • 58649083487 scopus 로고    scopus 로고
    • From randomized controlled trials to observational studies
    • Silverman SL. From randomized controlled trials to observational studies. Am J Med 2009; 122: 114-20.
    • (2009) Am J Med , vol.122 , pp. 114-120
    • Silverman, S.L.1
  • 4
    • 77950525609 scopus 로고    scopus 로고
    • Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register
    • Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP, Hyrich KL. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010; 49: 563-70.
    • (2010) Rheumatology (Oxford) , vol.49 , pp. 563-570
    • Lord, P.A.1    Farragher, T.M.2    Lunt, M.3    Watson, K.D.4    Symmons, D.P.5    Hyrich, K.L.6
  • 5
    • 70349464351 scopus 로고    scopus 로고
    • British Society for Rheumatology Biologics Register. Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity
    • Hyrich KL, Deighton C, Watson KD; BSRBR Control Centre Consortium, Symmons DP, Lunt M; British Society for Rheumatology Biologics Register. Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology (Oxford) 2009; 48: 1323-7.
    • (2009) Rheumatology (Oxford) , vol.48 , pp. 1323-1327
    • Hyrich, K.L.1    Deighton, C.2    Watson, K.D.3    Symmons, D.P.4    Lunt, M.5
  • 6
    • 79951691645 scopus 로고    scopus 로고
    • British Society for Rheumatology Biologics Register (B.S.R.B.R). Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008
    • Hyrich KL, Watson KD, Lunt M, Symmons DP; British Society for Rheumatology Biologics Register (BSRBR). Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford) 2011;50: 117-23.
    • (2011) Rheumatology (Oxford) , vol.50 , pp. 117-123
    • Hyrich, K.L.1    Watson, K.D.2    Lunt, M.3    Symmons, D.P.4
  • 7
    • 85027910087 scopus 로고    scopus 로고
    • for the ARTIS Study group. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
    • Nov 27. Epub
    • Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, Askling J; for the ARTIS Study group. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis 2013;Nov 27. Epub
    • (2013) Ann Rheum Dis
    • Neovius, M.1    Arkema, E.V.2    Olsson, H.3    Eriksson, J.K.4    Kristensen, L.E.5    Simard, J.F.6    Askling, J7
  • 8
    • 84868135421 scopus 로고    scopus 로고
    • Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors:drug-specific comparisons in the Swedish Biologics Register
    • Simard JF, Neovius M, Askling J; ARTIS Study Group. Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors:drug-specific comparisons in the Swedish Biologics Register. Arthritis Rheum 2012; 64: 3502-10.
    • (2012) Arthritis Rheum , vol.64 , pp. 3502-3510
    • Simard, J.F.1    Neovius, M.2    Askling, J.3
  • 9
    • 77957666794 scopus 로고    scopus 로고
    • Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register
    • Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res 2010; 10: 1362-9.
    • (2010) Arthritis Care Res , vol.10 , pp. 1362-1369
    • Kristensen, L.E.1    Karlsson, J.A.2    Englund, M.3    Petersson, I.F.4    Saxne, T.5    Geborek, P.6
  • 11
    • 84878412266 scopus 로고    scopus 로고
    • Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor a inhibitor therapy: results from the Danish nationwide DANBIO registry
    • Glintborg B, Østergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, Hansen A, Schlemmer A, Fana V, Lindegaard HM, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor a inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 2013; 72: 1149-55.
    • (2013) Ann Rheum Dis , vol.72 , pp. 1149-1155
    • Glintborg, B.1    Østergaard, M.2    Krogh, N.S.3    Tarp, U.4    Manilo, N.5    Loft, A.G.6    Hansen, A.7    Schlemmer, A.8    Fana, V.9    Lindegaard, H.M.10
  • 12
    • 84871055521 scopus 로고    scopus 로고
    • Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry
    • Ornbjerg LM, Ostergaard M, Bøyesen P, Krogh NS, Thormann A, Tarp U, Poulsen UE, Espesen J, Ringsdal VS, Graudal N, et al. Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2013; 72: 57-63.
    • (2013) Ann Rheum Dis , vol.72 , pp. 57-63
    • Ornbjerg, L.M.1    Ostergaard, M.2    Bøyesen, P.3    Krogh, N.S.4    Thormann, A.5    Tarp, U.6    Poulsen, U.E.7    Espesen, J.8    Ringsdal, V.S.9    Graudal, N.10
  • 13
    • 78149479826 scopus 로고    scopus 로고
    • Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry
    • Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010; 69: 2002-8.
    • (2010) Ann Rheum Dis , vol.69 , pp. 2002-2008
    • Glintborg, B.1    Ostergaard, M.2    Krogh, N.S.3    Dreyer, L.4    Kristensen, H.L.5    Hetland, M.L.6
  • 14
    • 74849094402 scopus 로고    scopus 로고
    • Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
    • Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62: 22-32.
    • (2010) Arthritis Rheum , vol.62 , pp. 22-32
    • Hetland, M.L.1    Christensen, I.J.2    Tarp, U.3    Dreyer, L.4    Hansen, A.5    Hansen, I.T.6    Kollerup, G.7    Linde, L.8    Lindegaard, H.M.9    Poulsen, U.E.10
  • 15
    • 84857233379 scopus 로고    scopus 로고
    • BIOBADASER 2.0 Study Group. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0
    • Gómez-Reino JJ, Rodríguez-Lozano C, Campos-Fernández C, Montoro M, Descalzo Má, Carmona L; BIOBADASER 2.0 Study Group. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis 2012; 71: 382-5.
    • (2012) Ann Rheum Dis , vol.71 , pp. 382-385
    • Gómez-Reino, J.J.1    Rodríguez-Lozano, C.2    Campos-Fernández, C.3    Montoro, M.4    Descalzo, Má.5    Carmona, L.6
  • 17
    • 84862563304 scopus 로고    scopus 로고
    • A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry
    • Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, Dehoratius R, Kishimoto M, Kremer JM. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012; 71: 1134-42.
    • (2012) Ann Rheum Dis , vol.71 , pp. 1134-1142
    • Greenberg, J.D.1    Reed, G.2    Decktor, D.3    Harrold, L.4    Furst, D.5    Gibofsky, A.6    Dehoratius, R.7    Kishimoto, M.8    Kremer, J.M.9
  • 20
    • 67449128733 scopus 로고    scopus 로고
    • The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection
    • Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68: 777-83.
    • (2009) Ann Rheum Dis , vol.68 , pp. 777-783
    • Rudwaleit, M.1    van der Heijde, D.2    Landewe, R.3    Listing, J.4    Akkoc, N.5    Brandt, J.6    Braun, J.7    Chou, C.T.8    Collantes-Estevez, E.9    Dougados, M.10
  • 22
    • 39449132386 scopus 로고    scopus 로고
    • The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study
    • Heiberg MS, Koldingsnes W, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, Kvien TK. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008; 59: 234-40.
    • (2008) Arthritis Rheum , vol.59 , pp. 234-240
    • Heiberg, M.S.1    Koldingsnes, W.2    Mikkelsen, K.3    Rodevand, E.4    Kaufmann, C.5    Mowinckel, P.6    Kvien, T.K.7
  • 23
    • 79959978514 scopus 로고    scopus 로고
    • Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry
    • Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol 2011; 38: 1273-81.
    • (2011) J Rheumatol , vol.38 , pp. 1273-1281
    • Markenson, J.A.1    Gibofsky, A.2    Palmer, W.R.3    Keystone, E.C.4    Schiff, M.H.5    Feng, J.6    Baumgartner, S.W.7
  • 25
    • 33744466292 scopus 로고    scopus 로고
    • Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis
    • Finckh A, Simard JF, Gabay C, Guerne PA. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 746-52.
    • (2006) Ann Rheum Dis , vol.65 , pp. 746-752
    • Finckh, A.1    Simard, J.F.2    Gabay, C.3    Guerne, P.A.4
  • 26
    • 84887489815 scopus 로고    scopus 로고
    • The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis
    • Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013; 72: 1947-55.
    • (2013) Ann Rheum Dis , vol.72 , pp. 1947-1955
    • Garces, S.1    Demengeot, J.2    Benito-Garcia, E.3
  • 28
    • 33947594031 scopus 로고    scopus 로고
    • The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis
    • Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, Zhou L, Peloso P. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007; 25: 40-6.
    • (2007) Clin Exp Rheumatol , vol.25 , pp. 40-46
    • Dore, R.K.1    Mathews, S.2    Schechtman, J.3    Surbeck, W.4    Mandel, D.5    Patel, A.6    Zhou, L.7    Peloso, P.8
  • 29
    • 0036720662 scopus 로고    scopus 로고
    • Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden
    • Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61: 793-8.
    • (2002) Ann Rheum Dis , vol.61 , pp. 793-798
    • Geborek, P.1    Crnkic, M.2    Petersson, I.F.3    Saxne, T.4
  • 31
    • 79959260432 scopus 로고    scopus 로고
    • Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study
    • Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 2011; 13: R94.
    • (2011) Arthritis Res Ther , vol.13 , pp. R94
    • Arends, S.1    Brouwer, E.2    van der Veer, E.3    Groen, H.4    Leijsma, M.K.5    Houtman, P.M.6    Th. A. Jansen, T.L.7    Kallenberg, C.G.8    Spoorenberg, A.9
  • 32
    • 33751416149 scopus 로고    scopus 로고
    • Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
    • Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 1558-65.
    • (2006) Rheumatology (Oxford) , vol.45 , pp. 1558-1565
    • Hyrich, K.L.1    Watson, K.D.2    Silman, A.J.3    Symmons, D.P.4
  • 33
    • 79551658174 scopus 로고    scopus 로고
    • Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry
    • Glintborg B, Ostergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS, Rifbjerg-Madsen S, Lorenzen T, Hetland ML. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011; 63: 382-90.
    • (2011) Arthritis Rheum , vol.63 , pp. 382-390
    • Glintborg, B.1    Ostergaard, M.2    Dreyer, L.3    Krogh, N.S.4    Tarp, U.5    Hansen, M.S.6    Rifbjerg-Madsen, S.7    Lorenzen, T.8    Hetland, M.L.9
  • 34
    • 77950525609 scopus 로고    scopus 로고
    • Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register
    • Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP, Hyrich KL. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010; 49: 563-70.
    • (2010) Rheumatology (Oxford) , vol.49 , pp. 563-570
    • Lord, P.A.1    Farragher, T.M.2    Lunt, M.3    Watson, K.D.4    Symmons, D.P.5    Hyrich, K.L.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.